英国发明透明止痛贴 可12小时持续给药

2015-12-18 徐青 健康界

英国华威大学(University of Warwick)的研究者宣布他们和华威大学校办企业Medherent一起发明了世界上首例通过皮肤持续注入药物的布洛芬透明贴片。 该贴片的聚合物基使用的是粘合剂公司Bostick的聚合技术,研究者可以将大量止痛药放到该聚合物基上,药物最多可占贴片总重量的30%,比现有止痛贴和布洛芬凝胶的药量高出5到10倍。 现有的口服止痛药和布洛芬凝胶很难控制用量,

英国华威大学(University of Warwick)的研究者宣布他们和华威大学校办企业Medherent一起发明了世界上首例通过皮肤持续注入药物的布洛芬透明贴片。

该贴片的聚合物基使用的是粘合剂公司Bostick的聚合技术,研究者可以将大量止痛药放到该聚合物基上,药物最多可占贴片总重量的30%,比现有止痛贴和布洛芬凝胶的药量高出5到10倍。

现有的口服止痛药和布洛芬凝胶很难控制用量,而这种贴片使用经皮技术,可以连续12小时稳定给药。这为未来发展新型长效非处方止痛药铺平了道路,也会有助于患有关节炎、神经痛和背痛等慢性病的患者减轻疼痛。

这种透明贴片外观比创可贴更好看,粘性更好,并且很容易移除。

华威大学化学家David Haddleton教授说:“现在市场上很多贴片根本不含任何止痛药物,而我们的技术却可以将有效药物成分如布洛芬聚合到贴片上,并可以精确控制用量。未来我们还会提高药量和粘性等问题,最大程度提高舒适度。”目前只有少数几种聚合基可用来制造这种贴片,也只有为数不多几种药物可以在这几种聚合基上分解。

Medherant首席执行官Nigel Davis称,这款贴片将在两年内面市。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=58261, encodeId=76245826195, content=太好了, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4e21675717, createdName=卡莲, createdTime=Mon Jan 18 21:48:00 CST 2016, time=2016-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58262, encodeId=b54b582627c, content=科技在进步, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4e21675717, createdName=卡莲, createdTime=Mon Jan 18 21:48:00 CST 2016, time=2016-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58263, encodeId=4df45826368, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4e21675717, createdName=卡莲, createdTime=Mon Jan 18 21:48:00 CST 2016, time=2016-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405499, encodeId=797214054993d, content=<a href='/topic/show?id=597b631634d' target=_blank style='color:#2F92EE;'>#止痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63163, encryptionId=597b631634d, topicName=止痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8da42553722, createdName=zhangxingru, createdTime=Sun Dec 20 07:55:00 CST 2015, time=2015-12-20, status=1, ipAttribution=)]
    2016-01-18 卡莲

    太好了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=58261, encodeId=76245826195, content=太好了, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4e21675717, createdName=卡莲, createdTime=Mon Jan 18 21:48:00 CST 2016, time=2016-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58262, encodeId=b54b582627c, content=科技在进步, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4e21675717, createdName=卡莲, createdTime=Mon Jan 18 21:48:00 CST 2016, time=2016-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58263, encodeId=4df45826368, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4e21675717, createdName=卡莲, createdTime=Mon Jan 18 21:48:00 CST 2016, time=2016-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405499, encodeId=797214054993d, content=<a href='/topic/show?id=597b631634d' target=_blank style='color:#2F92EE;'>#止痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63163, encryptionId=597b631634d, topicName=止痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8da42553722, createdName=zhangxingru, createdTime=Sun Dec 20 07:55:00 CST 2015, time=2015-12-20, status=1, ipAttribution=)]
    2016-01-18 卡莲

    科技在进步

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=58261, encodeId=76245826195, content=太好了, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4e21675717, createdName=卡莲, createdTime=Mon Jan 18 21:48:00 CST 2016, time=2016-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58262, encodeId=b54b582627c, content=科技在进步, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4e21675717, createdName=卡莲, createdTime=Mon Jan 18 21:48:00 CST 2016, time=2016-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58263, encodeId=4df45826368, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4e21675717, createdName=卡莲, createdTime=Mon Jan 18 21:48:00 CST 2016, time=2016-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405499, encodeId=797214054993d, content=<a href='/topic/show?id=597b631634d' target=_blank style='color:#2F92EE;'>#止痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63163, encryptionId=597b631634d, topicName=止痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8da42553722, createdName=zhangxingru, createdTime=Sun Dec 20 07:55:00 CST 2015, time=2015-12-20, status=1, ipAttribution=)]
    2016-01-18 卡莲

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=58261, encodeId=76245826195, content=太好了, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4e21675717, createdName=卡莲, createdTime=Mon Jan 18 21:48:00 CST 2016, time=2016-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58262, encodeId=b54b582627c, content=科技在进步, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4e21675717, createdName=卡莲, createdTime=Mon Jan 18 21:48:00 CST 2016, time=2016-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58263, encodeId=4df45826368, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4e21675717, createdName=卡莲, createdTime=Mon Jan 18 21:48:00 CST 2016, time=2016-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405499, encodeId=797214054993d, content=<a href='/topic/show?id=597b631634d' target=_blank style='color:#2F92EE;'>#止痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63163, encryptionId=597b631634d, topicName=止痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8da42553722, createdName=zhangxingru, createdTime=Sun Dec 20 07:55:00 CST 2015, time=2015-12-20, status=1, ipAttribution=)]